Get the latest Septerna, Inc. (SEPN) stock news and headlines to help you in your trading and investing decisions.

There are hundreds of conditions that have itch as an underlying symptom, according to Brian S. Kim, MD, MTR, the Sol and Clara Kest professor of dermatology and vice chair of research at Icahn School ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...

About Septerna Inc. Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discover ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native ...

Septerna (NASDAQ:SEPN – Get Free Report) is projected to announce its Q1 2025 earnings results on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

4 analysts have shared their evaluations of Septerna (NASDAQ:SEPN) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...